FDA approves first targeted therapy for HER2-low breast cancer

Radiation before mastectomy cuts time delays for reconstructive surgery in breast cancer patients

Researchers at MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays, and improved patient satisfaction.

April 12, 2024

Vol.50 No.15

Drugs & Targets

FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors

FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

April 12, 2024

Vol.50 No.15

In Brief

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

Antonio C. Wolff, chair of the Breast Cancer Committee for the ECOG-ACRIN Cancer Research Group, will co-lead the Breast Cancer Steering Committee for NCI. He began the three-year term on April 1.

April 05, 2024

Vol.50 No.14

Clinical Roundup

Study finds TNBC tumors with an increase in immune cells have lower risk of recurrence after surgery

A multicenter, international study suggests that people who have early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes within their tumors may have a lower risk of recurrence and better survival rates, even when not treated with chemotherapy.

April 05, 2024

Vol.50 No.14

In the Archives

Women’s History Month—How “Dr. Susan Love’s Breast Book” has remained the “bible” for women with breast cancer since 1990

When Stephanie Graff was a breast oncology fellow in 2010, one of her patients brought a marked up copy of “Dr. Susan Love’s Breast Book” to an appointment.

March 29, 2024

Vol.50 No.13

By Alexandria Carolan

Clinical Roundup

UCLA: Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence

A novel treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a phase III trial co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.

March 29, 2024

Vol.50 No.13

FDA approves first targeted therapy for HER2-low breast cancer

YOU MAY BE INTERESTED IN

Radiation before mastectomy cuts time delays for reconstructive surgery in breast cancer patients

FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

Study finds TNBC tumors with an increase in immune cells have lower risk of recurrence after surgery

Women’s History Month—How “Dr. Susan Love’s Breast Book” has remained the “bible” for women with breast cancer since 1990

UCLA: Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence

Renew today!

Subscriber content

Login